153 related articles for article (PubMed ID: 10438728)
1. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.
Byrd JC; Shinn C; Ravi R; Willis CR; Waselenko JK; Flinn IW; Dawson NA; Grever MR
Blood; 1999 Aug; 94(4):1401-8. PubMed ID: 10438728
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
3. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
[TBL] [Abstract][Full Text] [Related]
4. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.
Escobar-Díaz E; López-Martín EM; Hernández del Cerro M; Puig-Kroger A; Soto-Cerrato V; Montaner B; Giralt E; García-Marco JA; Pérez-Tomás R; Garcia-Pardo A
Leukemia; 2005 Apr; 19(4):572-9. PubMed ID: 15744353
[TBL] [Abstract][Full Text] [Related]
5. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Khan SB; Maududi T; Barton K; Ayers J; Alkan S
Br J Haematol; 2004 Apr; 125(2):156-61. PubMed ID: 15059137
[TBL] [Abstract][Full Text] [Related]
6. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
7. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
8. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient.
Rabizadeh E; Bairey O; Aviram A; Ben-Dror I; Shaklai M; Zimra Y
Eur J Haematol; 2001 Apr; 66(4):263-71. PubMed ID: 11380606
[TBL] [Abstract][Full Text] [Related]
11. Chrysin induces apoptosis in peripheral blood lymphocytes isolated from human chronic lymphocytic leukemia.
Zaric M; Mitrovic M; Nikolic I; Baskic D; Popovic S; Djurdjevic P; Milosavljevic Z; Zelen I
Anticancer Agents Med Chem; 2015; 15(2):189-95. PubMed ID: 25257897
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
13. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
14. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells.
Rajgolikar G; Chan KK; Wang HC
Breast Cancer Res Treat; 1998 Sep; 51(1):29-38. PubMed ID: 9877027
[TBL] [Abstract][Full Text] [Related]
15. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Byrd JC; Lucas DM; Mone AP; Kitner JB; Drabick JJ; Grever MR
Blood; 2003 Jun; 101(11):4547-50. PubMed ID: 12595316
[TBL] [Abstract][Full Text] [Related]
16. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.
Kitada S; Andersen J; Akar S; Zapata JM; Takayama S; Krajewski S; Wang HG; Zhang X; Bullrich F; Croce CM; Rai K; Hines J; Reed JC
Blood; 1998 May; 91(9):3379-89. PubMed ID: 9558396
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Byrd JC; Marcucci G; Parthun MR; Xiao JJ; Klisovic RB; Moran M; Lin TS; Liu S; Sklenar AR; Davis ME; Lucas DM; Fischer B; Shank R; Tejaswi SL; Binkley P; Wright J; Chan KK; Grever MR
Blood; 2005 Feb; 105(3):959-67. PubMed ID: 15466934
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
[TBL] [Abstract][Full Text] [Related]
19. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
[TBL] [Abstract][Full Text] [Related]
20. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]